Drug Profile
DABO 1220
Alternative Names: MC 1220Latest Information Update: 13 Jul 2007
Price :
$50
*
At a glance
- Originator Idenix Pharmaceuticals
- Developer Idenix Pharmaceuticals; Universita degli Studi di Roma; University of Cagliari
- Class Antivirals; Pyrimidines
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 13 Jul 2007 Discontinued - Preclinical for HIV infections prevention in France (Topical)
- 13 Jul 2007 Discontinued - Preclinical for HIV infections prevention in Italy (Topical)
- 13 Jul 2007 Discontinued - Preclinical for HIV infections prevention in USA (Topical)